<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Eur J Nucl Med Mol Imaging</journal-id>
      <journal-id journal-id-type="iso-abbrev">Eur. J. Nucl. Med. Mol. Imaging</journal-id>
      <journal-title-group>
        <journal-title>European Journal of Nuclear Medicine and Molecular Imaging</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">1619-7070</issn>
      <issn pub-type="epub">1619-7089</issn>
      <publisher>
        <publisher-name>Springer Berlin Heidelberg</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">18175115</article-id>
      <article-id pub-id-type="pmc">2292795</article-id>
      <article-id pub-id-type="publisher-id">660</article-id>
      <article-id pub-id-type="doi">10.1007/s00259-007-0660-6</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Original Article</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>The diagnostic value of <sup>124</sup>I-PET in patients with differentiated thyroid cancer</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name>
            <surname>Phan</surname>
            <given-names>Ha T. T.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Jager</surname>
            <given-names>Pieter L.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff6">6</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Paans</surname>
            <given-names>Anne M. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Plukker</surname>
            <given-names>John T. M.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sturkenboom</surname>
            <given-names>M. G. G.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
          <xref ref-type="aff" rid="Aff3">3</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sluiter</surname>
            <given-names>W. J.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff4">4</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Wolffenbuttel</surname>
            <given-names>Bruce H. R.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Dierckx</surname>
            <given-names>Rudi A. J. O.</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Links</surname>
            <given-names>Thera P.</given-names>
          </name>
          <address>
            <phone>+31-50-3613962</phone>
            <fax>+31-50-3619392</fax>
            <email>t.p.links@int.umcg.nl</email>
          </address>
          <xref ref-type="aff" rid="Aff5">5</xref>
        </contrib>
        <aff id="Aff1"><label>1</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 1981</institution-id><institution-id institution-id-type="GRID">grid.4830.f</institution-id><institution>Department of Nuclear Medicine and Molecular Imaging, University Medical Center Groningen, </institution><institution>University of Groningen, </institution></institution-wrap>Groningen, The Netherlands </aff>
        <aff id="Aff2"><label>2</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 1981</institution-id><institution-id institution-id-type="GRID">grid.4830.f</institution-id><institution>Department of Surgical Oncology, University Medical Center Groningen, </institution><institution>University of Groningen, </institution></institution-wrap>Groningen, The Netherlands </aff>
        <aff id="Aff3"><label>3</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 1981</institution-id><institution-id institution-id-type="GRID">grid.4830.f</institution-id><institution>Department of Hospital Pharmacy, University Medical Center Groningen, </institution><institution>University of Groningen, </institution></institution-wrap>Groningen, The Netherlands </aff>
        <aff id="Aff4"><label>4</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 1981</institution-id><institution-id institution-id-type="GRID">grid.4830.f</institution-id><institution>Department of Pathology &amp; Laboratory Medicine, University Medical Center Groningen, </institution><institution>University of Groningen, </institution></institution-wrap>Groningen, The Netherlands </aff>
        <aff id="Aff5"><label>5</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0004 0407 1981</institution-id><institution-id institution-id-type="GRID">grid.4830.f</institution-id><institution>Department of Endocrinology, University Medical Center Groningen, </institution><institution>University of Groningen, </institution></institution-wrap>Hanzeplein 1, P.O. Box 30.001, Groningen, 9700 RB The Netherlands </aff>
        <aff id="Aff6"><label>6</label><institution-wrap><institution-id institution-id-type="ISNI">0000 0001 0699 7567</institution-id><institution-id institution-id-type="GRID">grid.411657.0</institution-id><institution>Department of Nuclear Medicine, </institution><institution>McMaster University Medical Center Site, </institution></institution-wrap>Hamilton, Canada </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>4</day>
        <month>1</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>4</day>
        <month>1</month>
        <year>2008</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <year>2008</year>
      </pub-date>
      <volume>35</volume>
      <issue>5</issue>
      <fpage>958</fpage>
      <lpage>965</lpage>
      <history>
        <date date-type="received">
          <day>27</day>
          <month>9</month>
          <year>2007</year>
        </date>
        <date date-type="accepted">
          <day>18</day>
          <month>11</month>
          <year>2007</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2007</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Background</title>
          <p>The purpose of this prospective study was to evaluate the clinical diagnostic value of iodine-124 (<sup>124</sup>I)-positron emission tomography (PET) in patients with advanced differentiated thyroid carcinoma (DTC) and to compare the <sup>124</sup>I-PET imaging results with the <sup>131</sup>I whole-body scan (WBS).</p>
        </sec>
        <sec>
          <title>Materials and methods</title>
          <p>Twenty patients with histologically proven advanced DTC (including T4, extra-nodal tumour growth, or distant metastases) underwent diagnostic <sup>131</sup>I-WBS, <sup>124</sup>I-PET scan, and post-treatment <sup>131</sup>I-WBS 4&#xA0;months after ablation. The findings on the <sup>124</sup>I-PET were compared with the findings on the diagnostic and post-therapeutic <sup>131</sup>I-WBS and were also correlated with radiologic and/or cytological investigations.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>
<sup><italic>124</italic></sup>
<italic>I-PET vs diagnostic </italic>
<sup><italic>131</italic></sup>
<italic>I-WBS</italic>. Eleven patients showed uptake on the <sup>124</sup>I-PET. Only 3 of these 11 patients also showed uptake on the diagnostic <sup>131</sup>I scan, but the uptake was more clearly visible and the abnormalities were more extensive on the <sup>124</sup>I-PET. <sup><italic>124</italic></sup>
<italic>I-PET vs post-treatment </italic>
<sup><italic>131</italic></sup>
<italic>I-WBS</italic>. Eleven patients showed uptake on the <sup>124</sup>I-PET, which was also visible on the post-treatment scan in nine patients; in the other two patients, no uptake was observed on the post-treatment scan and no anatomical localisation could be confirmed. Two patients showed only uptake on the post-treatment scan without uptake on the <sup>124</sup>I-PET: in one, the uptake was confirmed by MRI, and in the other, no anatomical localisation was found. In seven patients, no uptake was observed on both the scans.</p>
        </sec>
        <sec>
          <title>Conclusion</title>
          <p>
<sup>124</sup>I-PET proved to be a superior diagnostic tool as compared to low-dose diagnostic <sup>131</sup>I scans and adequately predicted findings on subsequent high-dose post-treatment <sup>131</sup>I scans.</p>
        </sec>
      </abstract>
      <kwd-group xml:lang="en">
        <title>Keywords</title>
        <kwd>Iodine-124</kwd>
        <kwd>Positron emission tomography</kwd>
        <kwd>Differentiated thyroid cancer</kwd>
        <kwd>Diagnostic value</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2008</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1" sec-type="introduction">
      <title>Introduction</title>
      <p>Papillary and follicular thyroid cancer are the most frequent histological types of thyroid cancer (85-90%) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Total thyroidectomy with or without lymph node dissection is the initial therapy, followed by radioactive iodine therapy.</p>
      <p>In the routine follow-up of low-risk patients, diagnostic <sup>131</sup>I whole-body scanning (WBS) is not recommended in the recently published guidelines [<xref ref-type="bibr" rid="CR3">3</xref>] (<ext-link ext-link-type="uri" xlink:href="http://www.british-thyroid-association.org/draft_thyca_23.12.06.pdf">http://www.british-thyroid-association.org/draft_thyca_23.12.06.pdf</ext-link>; <ext-link ext-link-type="uri" xlink:href="http://www.oncoline.nl/uploaded/docs/Schildkliercarcinoom/schildklier%20ebro/richtlijn%20schildklier.pdf">http://www.oncoline.nl/uploaded/docs/Schildkliercarcinoom/schildklier%20ebro/ijn%20schildklier.pdf</ext-link>), but is still considered to be valuable in the follow-up of the high-risk patients. Measurement of the serum level of thyroglobulin (Tg), under recombinant human thyroid-stimulating hormone (rhTSH) stimulation or suppression, and ultrasonography have gained a more central role in monitoring for recurrent thyroid cancer [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>-<xref ref-type="bibr" rid="CR7">7</xref>] (<ext-link ext-link-type="uri" xlink:href="http://www.british-thyroid-association.org/draft_thyca_23.12.06.pdf">http://www.british-thyroid-association.org/draft_thyca_23.12.06.pdf</ext-link>). In patients with increasing or elevated Tg, a blind treatment with high-dose <sup>131</sup>I can be applied, followed by a post-treatment <sup>131</sup>I scan which also serves as a diagnostic tool [<xref ref-type="bibr" rid="CR21">21</xref>]. However, with this strategy, unnecessary high radiation exposure and high TSH level must be taken into account especially in patients who subsequently have no <sup>131</sup>I uptake on their post-treatment scan. Improvement of diagnostic imaging for the detection of recurrent or metastatic disease and a better (anatomical) localisation, e.g. using advanced imaging technique such as <sup>124</sup>I-positron emission tomography (PET)/CT would allow more selective application of <sup>131</sup>I therapy and might avoid unnecessary high-dose treatments.</p>
      <p>Several iodine isotopes such as <sup>123</sup>I, <sup>125</sup>I, <sup>131</sup>I play an important role in nuclear medicine, both for diagnostic purposes and for therapy. Iodine-124 is a positron emitting isotope and therefore suitable PET imaging. Its half-life is 4.2&#xA0;days with a very complex decay scheme leading to extra non- or partially annihilation radiation coincidence detection [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>]. Approximately 23% of the desintegrations results in positron emissions.</p>
      <p>While the radioisotopes <sup>123</sup>I and especially <sup>131</sup>I are used on a wide scale in diagnosis and treatment of all thyroid disorders, <sup>124</sup>I has received little attention. This isotope would allow thyroid cancer imaging using the high-resolution PET technique [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR10">10</xref>]. Iodine-124 has so far mainly been used for dosimetry or thyroid volume measurements [<xref ref-type="bibr" rid="CR10">10</xref>-<xref ref-type="bibr" rid="CR16">16</xref>]. However, the recent development of combined PET/CT scanners may increase clinical application in thyroid cancer patients, as detailed anatomical information is combined with the location of iodine positive tissue [<xref ref-type="bibr" rid="CR17">17</xref>]. Iodine-124 has recently been applied for staging of differentiated thyroid cancer, as reported in a few case reports and small series, with promising results [<xref ref-type="bibr" rid="CR17">17</xref>-<xref ref-type="bibr" rid="CR19">19</xref>]. However, the diagnostic value of <sup>124</sup>I-PET imaging as compared to (low- and high-dose) <sup>131</sup>I scintigraphy has to be further investigated.</p>
      <p>Iodine-124 PET may be able to detect recurrent or residual disease in differentiated thyroid carcinoma (DTC) with a higher sensitivity than the conventional (diagnostic) <sup>131</sup>I scans because of the higher spatial resolution. In this way, <sup>124</sup>I-PET imaging could possibly be a useful diagnostic tool during the follow-up of DTC patients. Therefore, we have performed a pilot study in the early treatment phase of thyroid cancer to get an impression of the diagnostic potential of <sup>124</sup>I-PET for detection and staging of advanced DTC. We compared the <sup>124</sup>I-PET imaging results with the diagnostic and post-treatment <sup>131</sup>I-WBS.</p>
    </sec>
    <sec id="Sec2" sec-type="materials|methods">
      <title>Materials and methods</title>
      <p>Twenty patients with histologically proven advanced DTC, including extrathyroidal tumour growth (T4), extra-nodal tumour growth or distant metastasis (M1), were examined in this study. These patients had undergone (near) total thyroidectomy. Four to 6&#xA0;weeks after surgery, diagnostic <sup>131</sup>I-WBS after 37&#xA0;MBq of <sup>131</sup>I was obtained, followed by an ablative dose of 5,550&#xA0;MBq <sup>131</sup>I. Post-treatment WBS was obtained after 10&#xA0;days. At the time of ablation, serum Tg and Tg antibodies (TgAb) levels were also determined.</p>
      <p>All 20 studied patients underwent diagnostic <sup>131</sup>I-WBS, <sup>124</sup>I-PET scan and post-treatment <sup>131</sup>I-WBS 4&#xA0;months after ablation therapy (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>). The Tg<sub>off</sub> levels (under TSH stimulation after thyroid hormone withdrawal or after rhTSH injection) were also measured just before the administration of the diagnostic low-dose <sup>131</sup>I. The Medical Ethics Committee of University Medical Center Groningen approved the study protocol, and all patients gave written informed consent.
<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>The diagram showed a schematic course of the investigations performed 4&#xA0;months after ablation</p></caption><graphic xlink:href="259_2007_660_Fig1_HTML" id="MO1"/></fig>
</p>
      <p>Tg was measured by immunoradiometric assay (Brahms, Henningsdorf, Germany), with a functional sensitivity (i.e. the Tg concentration with a vital capacity of 20%) of 0.3&#xA0;ng/ml as determined by the laboratory. Thyroglobulin antibodies (TgAb) were detected by both immunoradiometric assay (Brahms, Henningsdorf, Germany) with a cutoff of 60&#xA0;U/ml and by immunoluminometric assay (Abbott, Hoofddorp, Netherlands) on the Architect i 2000 platform (Abbott) with a cutoff of 4.1&#xA0;U/ml. Both cutoff concentrations were determined by Brahms and Abbott, respectively. In 19 patients, the Tg level was determined after thyroid hormone withdrawal and in one patient after rhTSH due to poor physical condition (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).
<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Patient characteristics and imaging results</p></caption><table frame="hsides" rules="groups"><thead><tr><th>Pt</th><th>Age, sex</th><th>TNM</th><th>Tg<sub>off</sub> (ng/ml)</th><th>TSH (mU/l)</th><th>
<sup>124</sup>I-PET</th><th>Pt <sup>131</sup>I-WBS</th><th>Dx <sup>131</sup>I-WBS</th><th>Validation</th></tr></thead><tbody><tr><td>1</td><td>59M</td><td>pT1N0M1</td><td>48</td><td>50</td><td>CV, pelvis +++</td><td>CV, pelvis +++</td><td>CV, pelvis +</td><td>MR cv: p, MRI pelvis:p</td></tr><tr><td>2</td><td>67F</td><td>fT4N1M1</td><td>201</td><td>48</td><td>Neck, thyroid bed +++, lung ++</td><td>Neck, thyroid bed +++ lung ++</td><td>Neck ++</td><td>CT lung: no abnormal lesions, MRI neck: p</td></tr><tr><td>3</td><td>85M</td><td>fT4N0M1</td><td>2.6<sup>a</sup>
</td><td>0.01<sup>a</sup>
</td><td>Skull, CV, pelvis +++</td><td>CV+++</td><td>CV +</td><td>Skull: p, MR cv: p<sup>b</sup>
</td></tr><tr><td>4</td><td>48F</td><td>pT4N1M0</td><td>49</td><td>77</td><td>Neck ++</td><td>Neck ++</td><td>-</td><td>MRI:neck: p</td></tr><tr><td>5</td><td>74F</td><td>pT4N1M0</td><td>&lt;0.30</td><td>44</td><td>Neck ++</td><td>Neck ++</td><td>-</td><td>MRI:neck: p</td></tr><tr><td>6</td><td>74M</td><td>fT2N0M1</td><td>691</td><td>&gt;200</td><td>Neck/SC +++</td><td>Neck/SC, pelvis +++</td><td>-</td><td>MRI pelvis: p<sup>b</sup>
</td></tr><tr><td>7</td><td>73F</td><td>fT4N1M0</td><td>105</td><td>56</td><td>Neck/thyroid bed +</td><td>Neck/thyroid bed ++</td><td>-</td><td>US neck/FNAC: p</td></tr><tr><td>8</td><td>18F</td><td>pT4N1M1</td><td>&lt;0.30</td><td>51</td><td>Pelvis ++</td><td>Pelvis +</td><td>-</td><td>MRI pelvis:p</td></tr><tr><td>9</td><td>39M</td><td>pT4N1M0</td><td>85</td><td>75</td><td>Neck +++</td><td>Neck +++</td><td>-</td><td>MRI neck: p</td></tr><tr><td>10</td><td>73F</td><td>pT4N1M0</td><td>3</td><td>43</td><td>Neck +</td><td>-</td><td>-</td><td>US neck and FNAC: inconclusive, FDG PET: n</td></tr><tr><td>11</td><td>59M</td><td>fT3N0M1</td><td>1680</td><td>73</td><td>Femur prosthesis ++</td><td>-</td><td>-</td><td>MRI pelvis/femur : reactive tissue around the femur prosthesis; FDG PET: lesions in costae and pelvis</td></tr><tr><td>12</td><td>73M</td><td>pT3N0M1</td><td>&lt;0.30</td><td>33 </td><td>-</td><td>skull ++</td><td>-</td><td>MRI skull: p, FDG PET: n</td></tr><tr><td>13</td><td>67M</td><td>pT4N0M0</td><td>&lt;0.30</td><td>142</td><td>-</td><td>pelvis +</td><td>-</td><td>X-pelvis: n, bone scan: n</td></tr><tr><td>14</td><td>42F</td><td>pT4N1M0</td><td>15</td><td>81</td><td>-</td><td>-</td><td>-</td><td>US neck and FNAC: n, FDG PET: n</td></tr><tr><td>15</td><td>49F</td><td>pT4N0M0</td><td>18</td><td>66</td><td>-</td><td>-</td><td>-</td><td>US neck and FNAC: n, FDG PET: n</td></tr><tr><td>16</td><td>59M</td><td>pT4NxM0</td><td>2.8</td><td>76</td><td>-</td><td>-</td><td>-</td><td>MRI neck, US neck and FNAC: n, FDG PET: n</td></tr><tr><td>17</td><td>68M</td><td>pT2N0M1</td><td>14</td><td>44</td><td>-</td><td>-</td><td>-</td><td>US neck/FNAC: n, FDG PET and CT: lung lesions</td></tr><tr><td>18</td><td>79F</td><td>fT4NxM0</td><td>1.6</td><td>53</td><td>-</td><td>-</td><td>-</td><td>MRI neck: p, US neck: lymph node not accessible for FNA, FDG PET: n</td></tr><tr><td>19</td><td>71F</td><td>fT4N0M0</td><td>0.54</td><td>36</td><td>-</td><td>-</td><td>-</td><td>-</td></tr><tr><td>20</td><td>37M</td><td>pT1N1bM0</td><td>&lt;0.30</td><td>95</td><td>-</td><td>-</td><td>-</td><td>-</td></tr></tbody></table><table-wrap-foot><p>
<italic>p</italic> Papillar, <italic>f</italic> follicular, <italic>Pt </italic>
<sup><italic>131</italic></sup>
<italic>I-WBS</italic> post-treatment <sup>131</sup>I-WBS, <italic>Dx </italic>
<sup><italic>131</italic></sup>
<italic>I-WBS</italic> diagnostic <sup>131</sup>I-WBS, <italic>CV</italic> cervical vertebrae, <italic>SC</italic> sternal clavicular, &#x2212; not visible, + just visible, ++ visible, +++ clearly visible, <italic>n</italic> negative, <italic>p</italic> positive, <italic>FNAC</italic> fine needle aspiration cytology, <italic>FDG-PET</italic> fluorodeoxyglucose positron emission tomography</p><p>
<sup>a</sup>rhTSH stimulated</p><p>
<sup>b</sup>In these two patients, no additional radiologic imaging of the neck (no. 3) and pelvis (no. 6) was performed to confirm the findings on the PET and <sup>131</sup>I-WBS due to poor physical condition and due to the lack curative therapeutic options</p></table-wrap-foot></table-wrap>
</p>
      <sec id="Sec3">
        <title>Tracer</title>
        <p>
<sup>124</sup>I-sodium iodide solution was obtained from Ritverc Isotope Products, St. Petersburg, Russia and was imported by I.D.B. Holland BV (Baarle-Nassau, The Netherlands). Radiochemical purity using instant thin layer chromatography and radionuclide purity using germanium (HP-Ge) detector were tested before release according to standard radiopharmaceutical procedures. Before use, the solution was filtered using a Millipore bacterial filter (0.22&#xA0;&#x3BC;m) and diluted with sterile saline. A sterility test was performed on each batch, but data were only available after administration due to the length of the test procedure (7&#xA0;days).</p>
      </sec>
      <sec id="Sec4">
        <title>PET scanning</title>
        <p>Diagnostic <sup>124</sup>I-PET imaging was performed 24&#xA0;h after intravenous administration of 74&#xA0;MBq of <sup>124</sup>I [<xref ref-type="bibr" rid="CR17">17</xref>]. A Siemens PET camera (Exact HR+, Knoxville, TN, USA) was used for imaging. The patient was positioned in the scanner, and a standard clinical whole-body PET study was performed in 2D ETTE mode over seven to eight positions (from the upper thigh up until the top of the skull) of 5-min emission and 3-min transmission, standard energy window setting of 350-650&#xA0;keV. Images were reconstructed with attenuation-weighted OSEM, two iterations and eight subsets. The total time needed for the scan was approximately 60&#xA0;min.</p>
        <p>In the initial four patients, the <sup>124</sup>I-PET images were repeated 96&#xA0;h after <sup>124</sup>I administration (thus, 72&#xA0;h after therapeutic dose of <sup>131</sup>I) using the same acquisition settings as after 24&#xA0;h. Narrowing of the energy window (425-650 or 460-562&#xA0;keV, 3D mode) for <sup>124</sup>I-PET imaging during high-dose <sup>131</sup>I therapy to reduce the effects of &#x3B3;-rays (364, 637&#xA0;keV) of <sup>131</sup>I and <sup>124</sup>I (602&#xA0;keV) and to improve image quality, as described in the phantom study (and clinical application in one thyroid cancer patient) by Lubberink et al. [<xref ref-type="bibr" rid="CR20">20</xref>], was not possible in our institution due to technical reasons, e.g. camera characteristics. The 96-h <sup>124</sup>I-PET images were very noisy and blurred and were excluded from the study. This poor image quality could partially be explained by the poor statistics due to the very low radioactivity left in the body after 96&#xA0;h and partially by technical reasons as described above.</p>
      </sec>
      <sec id="Sec5">
        <title>Data analysis</title>
        <p>The <sup>131</sup>I-WBS and <sup>124</sup>I-PET scans were visually interpreted by two independent, experienced nuclear medicine physicians (HTP, PLJ). The findings on the <sup>124</sup>I-PET scans were compared with the findings on the diagnostic and post-therapeutic <sup>131</sup>I-WBS. Correlation with radiologic imaging (US, CT, MRI) and/or cytological (fine needle aspiration cytology, FNAC) investigation was done to confirm the findings or in case of discordant findings on the <sup>124</sup>I-PET scan and <sup>131</sup>I-WBS. If no abnormal uptake was seen on the PET scan and <sup>131</sup>I-WBS, additional radiologic imaging (MRI, US), with or without FNAC, and fluorodeoxyglucose (FDG) PET were also performed to detect local or metastatic disease and/or used as a follow-up diagnostic tool.</p>
      </sec>
    </sec>
    <sec id="Sec6" sec-type="results">
      <title>Results</title>
      <p>From December 2005 until April 2007, 20 consecutive patients with advanced DTC were included in this prospective study. The group consisted of ten women and ten men, median age of 67&#xA0;years (range 18-85&#xA0;years). Individual patient characteristics and the findings on the <sup>124</sup>I PET scan and <sup>131</sup>I-WBS are summarised in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.</p>
      <p>Physiological uptake of <sup>124</sup>I was observed in the salivary glands, esophagus, gastrointestinal tract and bladder as it is also normally seen on the <sup>131</sup>I scans.</p>
      <sec id="Sec7">
        <title><sup>124</sup>I-PET vs diagnostic <sup>131</sup>I-WBS</title>
        <p>Eleven patients (no. 1-11) showed uptake on the <sup>124</sup>I-PET scan. In only three of them (no. 1-3) was the uptake also observed on the diagnostic <sup>131</sup>I scan, but the uptake was clearer and the abnormalities were more extensive on the <sup>124</sup>I-PET scan (Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>). In nine patients (no. 12-20), no uptake was observed on both the scans. Results of additional radiologic imaging (MRI and/or US-FNAC) are also listed in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.
<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>This patient (no. 1) showed a clearly visible lesion in the cervical vertebrae on the <sup>124</sup>I-PET (<bold>a</bold>, <italic>arrow</italic>), comparable with the lesion visible on the post-treatment <sup>131</sup>I-WBS (<bold>c</bold>, <italic>arrow</italic>). This lesion was vaguely visible on the diagnostic <sup>131</sup>I-WBS (<bold>b</bold>, <italic>arrow</italic>). Physiologic uptake in the esophagus, gastrointestinal tract and bladder is observed on the <sup>124</sup>I-PET</p></caption><graphic xlink:href="259_2007_660_Fig2_HTML" id="MO2"/></fig>
</p>
        <p>It has also been noticed that the Tg<sub>off</sub> level (after endogenous TSH stimulation) was not detectable (&lt;0.30&#xA0;ng/ml, TSH &gt;30&#xA0;mU/L) without the presence of Tg antibodies in five (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>, no. 5, 8, 12, 13, 20) of the 20 patients. However, two of these five patients showed lesions on the <sup>124</sup>I-PET (and post-treatment <sup>131</sup>I scan) confirmed by MRI. Diagnostic <sup>131</sup>I-WBS was negative in all five.</p>
      </sec>
      <sec id="Sec8">
        <title><sup>124</sup>I-PET vs post-treatment <sup>131</sup>I-WBS</title>
        <p>Nine (no. 1-9) out of the 11 patients with uptake on the <sup>124</sup>I-PET scan had lesions which were also visible on the post-treatment scan (Fig.&#xA0;<xref rid="Fig3" ref-type="fig">3</xref>). In two patients (no. 10, 11), no uptake was observed on the post-treatment <sup>131</sup>I scan and no anatomical localisation could be confirmed. FDG PET showed, however, lesions in the costae and pelvis in patient no. 11 (Fig.&#xA0;<xref rid="Fig4" ref-type="fig">4</xref>).
<fig id="Fig3"><label>Fig.&#xA0;3</label><caption><p>This patient (no. 6) showed a clearly visible lesion in the left lower neck region or on the <sup>124</sup>I-PET (<bold>a</bold>, <italic>arrow</italic>), comparable with the lesion visible on the post-treatment <sup>131</sup>I-WBS (<bold>c</bold>, <italic>arrow</italic>). No uptake was observed on the diagnostic <sup>131</sup>I-WBS (<bold>b</bold>)</p></caption><graphic xlink:href="259_2007_660_Fig3_HTML" id="MO3"/></fig>
<fig id="Fig4"><label>Fig.&#xA0;4</label><caption><p>Clearly, uptake in the right costae (<italic>arrow</italic>) and left hip is seen on the FDG-PET (<bold>c</bold>) in patient no. 11, whereas the post-treatment <sup>131</sup>I-WBS (<bold>a</bold>) was negative. The <sup>124</sup>I-PET (<bold>b</bold>) showed only uptake around the femur prosthesis on the right side, which is also observed on the FDG-PET, which could be explained by reactive tissue on the MRI. The complementary uptake of radioiodine and FDG is also known as the flip-flop phenomenon, which was first described by Joensuu and Ahonen [<xref ref-type="bibr" rid="CR27">27</xref>]</p></caption><graphic xlink:href="259_2007_660_Fig4_HTML" id="MO4"/></fig>
</p>
        <p>Two patients (no. 12, 13) showed uptake on the post-treatment <sup>131</sup>I scan, which was not visible on the <sup>124</sup>I-PET scan: In one, MRI confirmed the <sup>131</sup>I uptake in the skull, and in the other, no anatomical localisation could be found for the <sup>131</sup>I uptake in the pelvis region. In seven patients (no. 14-20), no uptake was observed on both the scans. In four of seven patients (no. 14-17), no lesions could be found with MRI and/or US-FNAC; in one of these four (no. 17), FDG-PET showed uptake in the lungs which was confirmed by CT. One patient (no. 18) showed slightly enlarged lymph node in the superior mediastinum on the MRI which was not accessible for US-guided FNAC. In two patients (no. 19, 20), MRI/US of the neck will be obtained (due to patient delay). Results of additional radiologic imaging are listed in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>.</p>
      </sec>
    </sec>
    <sec id="Sec9" sec-type="discussion">
      <title>Discussion</title>
      <p>This pilot study showed that <sup>124</sup>I-PET detected more abnormalities in comparison to the diagnostic <sup>131</sup>I-WBS, but showed comparable findings with the post-treatment <sup>131</sup>I-WBS. Eleven patients had positive <sup>124</sup>I-PET scanning, and only three had visible abnormalities with the low-dose <sup>131</sup>I scan. Moreover, <sup>124</sup>I-PET also showed abnormalities in two of the five patients with undetectable Tg, while the low-dose diagnostic <sup>131</sup>I scan was negative in all five. These findings suggest that <sup>124</sup>I-PET better predicts the outcome of high-dose <sup>131</sup>I treatment and would be better suited as a diagnostic tool to base clinical decisions on such as additional surgery or application of high dose <sup>131</sup>I. Therefore, <sup>124</sup>I-PET should be performed before considering high-dose <sup>131</sup>I treatment. A negative <sup>124</sup>I-PET could mean omitting <sup>131</sup>I treatment, and further additional imaging should be performed to detect (non-iodine avid) metastatic disease.</p>
      <p>Two patients (no. 12, 13) showed uptake in the skull and pelvis region, respectively, on the post-treatment <sup>131</sup>I-WBS which was not visible on the <sup>124</sup>I-PET. Possible explanations for these findings might be the low dose of <sup>124</sup>I in which (small) lesions in the skull might be missed and false-positive uptake of <sup>131</sup>I in the bowel which could be mistaken for abnormality.</p>
      <p>Our results are in agreement with the study by Freudenberg et al. [<xref ref-type="bibr" rid="CR17">17</xref>]. In their study, 12 patients with advanced DTC underwent high-dose <sup>131</sup>I-WBS, <sup>124</sup>I-PET, CT, combined <sup>124</sup>I-PET/CT, FDG-PET and US post-thyroidectomy during routine clinical staging. The overall lesion detectability for high-dose <sup>131</sup>I-WBS was comparable with the <sup>124</sup>I-PET, 83 vs 87%, respectively. Moreover, combined <sup>124</sup>I-PET/CT modality, which showed an overall lesion detectability of 100%, resulted in a change of staging in two patients and a change in management in one.</p>
      <p>It has been questioned why <sup>124</sup>I-PET would be a suitable diagnostic tool when blind treatment is given anyway in the clinical practice. Blind treatment with high-dose <sup>131</sup>I in patients known with negative low-dose diagnostic <sup>131</sup>I scanning but with elevated Tg has been used as a diagnostic, therapeutic and prognostic tool. Patients without iodine accumulation on the post-treatment WBS, which could be an indication for tumour dedifferentiation, had a worse prognosis compared to those with a positive post-treatment WBS [<xref ref-type="bibr" rid="CR21">21</xref>]. Repeating high doses of <sup>131</sup>I may bear the risks in terms of long-term risk of secondary malignancies. In addition, repeated long-lasting TSH stimulation might have adverse effects on tumour growth. This aspect of long-lasting TSH stimulation may be prevented when performing the <sup>124</sup>I-PET after rhTSH stimulation before the decision of giving additional high-dose <sup>131</sup>I. However, comparative studies are needed to evaluate the yield of the <sup>124</sup>I-PET under endogenous TSH stimulation and after rhTSH stimulation.</p>
      <p>Additional advantages of <sup>124</sup>I-PET would include the better resolution of this tomographic method and the ease of combining this with CT data to increase the diagnostic value, as shown by Freudenberg et al. [<xref ref-type="bibr" rid="CR17">17</xref>]. Moreover, <sup>124</sup>I-PET would allow more precise dosimetric calculations [<xref ref-type="bibr" rid="CR25">25</xref>, <xref ref-type="bibr" rid="CR26">26</xref>, <xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>], although that was not a focus of this study.</p>
      <p>Another aspect which favours performing of <sup>124</sup>I-PET before blind high-dose <sup>131</sup>I is the radiation dose. The effective dose of <sup>124</sup>I is in the same order of magnitude as <sup>131</sup>I [<xref ref-type="bibr" rid="CR10">10</xref>, <xref ref-type="bibr" rid="CR22">22</xref>-<xref ref-type="bibr" rid="CR24">24</xref>]. The effective dose of <sup>124</sup>I-iodide is 0.095&#xA0;mSv/MBq with a thyroid uptake of 0% and increases to1.5&#xA0;mSv/MBq with a thyroid uptake of 35% [<xref ref-type="bibr" rid="CR23">23</xref>]. The total radiation exposure has been calculated at 7.0&#xA0;mSv for a dose of 74&#xA0;MBq <sup>124</sup>I. The administered dose is comparable to the dose administered for routine nuclear medicine scans. However, the total radiation exposure of <sup>124</sup>I is just a fraction compared to the total radiation exposure of the therapeutic dose of <sup>131</sup>I (340&#xA0;mSv for 5,550&#xA0;MBq [<xref ref-type="bibr" rid="CR23">23</xref>], which was also mentioned in the study by Freudenberg et al. [<xref ref-type="bibr" rid="CR17">17</xref>].</p>
      <p>The issue whether stunning is a real phenomenon and its clinical relevance/consequence is debatable. Stunning effect after (higher) diagnostic dose of <sup>131</sup>I has been described and discussed in the literature. The applied diagnostic <sup>131</sup>I dose could impair the ability of the residual thyroid carcinoma tissue to accumulate the subsequently applied high-dose <sup>131</sup>I dose. The degree of stunning probably depends on the absorbed radiation dose and the time between the diagnostic and therapeutic <sup>131</sup>I dose.</p>
      <p>Stunning was not seen with diagnostic <sup>131</sup>I doses of 185&#xA0;MBq (5&#xA0;mCi) or lower [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>], whereas stunning was frequently observed after a diagnostic dose of 370&#xA0;MBq (10&#xA0;mCi) <sup>131</sup>I [<xref ref-type="bibr" rid="CR32">32</xref>]. There is also evidence that a short time interval between the administration of the diagnostic and therapeutic <sup>131</sup>I dose may diminish the effect of stunning [<xref ref-type="bibr" rid="CR31">31</xref>]. Most authors who have described stunning administered the therapeutic <sup>131</sup>I dose several days after the completion of the diagnostic <sup>131</sup>I scan [<xref ref-type="bibr" rid="CR32">32</xref>-<xref ref-type="bibr" rid="CR35">35</xref>]. Stunning is not seen when the therapeutic dose is administered within several hours. Furthermore, the time interval between the administration of a high dose of <sup>131</sup>I and the performance of a post-therapy WBS may influence the observation of stunning [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR36">36</xref>]. A longer time interval allows more time for soft tissue clearance of <sup>131</sup>I, which results in a higher sensitivity of the post-therapy WBS. No stunning was seen at the post-therapy <sup>131</sup>I-WBS, performed 5-10&#xA0;days after doses of 1,110-3,700&#xA0;MBq (30-100&#xA0;mCi) <sup>131</sup>I after 74&#xA0;MBq (2&#xA0;mCi)) and 370&#xA0;MBq (mCi) diagnostic scan [<xref ref-type="bibr" rid="CR37">37</xref>].</p>
      <p>In our study, we used a rather a low dose of <sup>124</sup>I (74&#xA0;MBq) and a short interval (1&#xA0;day) between the administration of the diagnostic dose of <sup>124</sup>I and the administration of the therapeutic <sup>131</sup>I dose and a long interval (10&#xA0;days) between the therapeutic <sup>131</sup>I dose and the post-therapy <sup>131</sup>I-WBS. If stunning does exist after <sup>124</sup>I, it is therefore unlikely to have reduced the efficacy of <sup>131</sup>I treatment in our study.</p>
      <p>Iodine-124 is, however, poorly available with high costs, but the advantages of <sup>124</sup>I-PET could outweigh these disadvantages and can lead to more clinical application in the follow-up of DTC patients when <sup>124</sup>I will become more available.</p>
      <sec id="Sec10">
        <title>Conclusions</title>
        <p>In this study, <sup>124</sup>I-PET proved to be a superior diagnostic tool as compared to low-dose diagnostic <sup>131</sup>I scans and adequately predicted findings on subsequent high-dose post-treatment <sup>131</sup>I scans. In combination with the high resolution and the possibilities to combine with CT, this could lead to improved clinical decision making.</p>
      </sec>
    </sec>
  </body>
  <back>
    <ack>
      <title>Acknowledgements</title>
      <p>The authors thank the &#x201C;Innovatie Fonds UMCG&#x201D;, The Netherlands, for their grant support.</p>
      <sec id="d29e1923">
        <title>Open Access</title>
        <p>This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
      </sec>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sherman</surname>
              <given-names>SI</given-names>
            </name>
          </person-group>
          <article-title>Thyroid carcinoma</article-title>
          <source>Lancet</source>
          <year>2003</year>
          <volume>361</volume>
          <fpage>501</fpage>
          <lpage>511</lpage>
          <pub-id pub-id-type="doi">10.1016/S0140-6736(03)12488-9</pub-id>
          <pub-id pub-id-type="pmid">12583960</pub-id>
        </element-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ringel</surname>
              <given-names>MD</given-names>
            </name>
            <name>
              <surname>Ladenson</surname>
              <given-names>PW</given-names>
            </name>
          </person-group>
          <article-title>Controversies in the follow-up and management of well-differentiated thyroid cancer</article-title>
          <source>Endocr Relat Cancer</source>
          <year>2004</year>
          <volume>11</volume>
          <fpage>97</fpage>
          <lpage>116</lpage>
          <pub-id pub-id-type="doi">10.1677/erc.0.0110097</pub-id>
          <pub-id pub-id-type="pmid">15027888</pub-id>
        </element-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cooper</surname>
              <given-names>DS</given-names>
            </name>
            <name>
              <surname>Doherty</surname>
              <given-names>GM</given-names>
            </name>
            <name>
              <surname>Haugen</surname>
              <given-names>BR</given-names>
            </name>
            <name>
              <surname>Kloos</surname>
              <given-names>RT</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Mandel</surname>
              <given-names>SJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. The American Thyroid Association Guidelines Taskforce</article-title>
          <source>Thyroid</source>
          <year>2006</year>
          <volume>16</volume>
          <fpage>109</fpage>
          <lpage>142</lpage>
          <pub-id pub-id-type="doi">10.1089/thy.2006.16.109</pub-id>
          <pub-id pub-id-type="pmid">16420177</pub-id>
        </element-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cailleux</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Baudin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Travagli</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Ricard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Schlumberger</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Is diagnostic iodine-131 scanning useful after total thyroid ablation for differentiated thyroid cancer?</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2000</year>
          <volume>85</volume>
          <fpage>175</fpage>
          <lpage>178</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem.85.1.6310</pub-id>
          <pub-id pub-id-type="pmid">10634383</pub-id>
        </element-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Torlontano</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Attard</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Crocetti</surname>
              <given-names>U</given-names>
            </name>
            <name>
              <surname>Tumino</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Bruno</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Costante</surname>
              <given-names>G</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Follow-up of low-risk patients with papillary thyroid cancer: role of neck ultrasonography in detecting lymph node metastases</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2004</year>
          <volume>89</volume>
          <fpage>3402</fpage>
          <lpage>3407</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2003-031521</pub-id>
          <pub-id pub-id-type="pmid">15240622</pub-id>
        </element-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Baudin</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Do Cao</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Cailleux</surname>
              <given-names>AF</given-names>
            </name>
            <name>
              <surname>Leboulleux</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Travagli</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Schlumberger</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Positive predictive value of serum thyroglobulin levels, measured during the first year of follow-up after thyroid hormone withdrawal, in thyroid cancer patients</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2003</year>
          <volume>88</volume>
          <fpage>1107</fpage>
          <lpage>1111</lpage>
          <pub-id pub-id-type="doi">10.1210/jc.2002-021365</pub-id>
          <pub-id pub-id-type="pmid">12629092</pub-id>
        </element-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Menendez Torre</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Lopez Carballo</surname>
              <given-names>MT</given-names>
            </name>
            <name>
              <surname>Rodriguez Erdozain</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Forga Llenas</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Goni Iriarte</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Barberia Layana</surname>
              <given-names>JJ</given-names>
            </name>
          </person-group>
          <article-title>Prognostic value of thyroglobulin serum levels and <sup>131</sup>I whole body scan after initial treatment of low-risk differentiated thyroid cancer</article-title>
          <source>Thyroid</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>301</fpage>
          <lpage>306</lpage>
          <pub-id pub-id-type="doi">10.1089/105072504323030960</pub-id>
          <pub-id pub-id-type="pmid">15142364</pub-id>
        </element-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pentlow</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Graham</surname>
              <given-names>MC</given-names>
            </name>
            <name>
              <surname>Lambrecht</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Daghighian</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Bacharach</surname>
              <given-names>SL</given-names>
            </name>
            <name>
              <surname>Bendriem</surname>
              <given-names>B</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Quantitative imaging of iodine-124 with PET</article-title>
          <source>J Nucl Med</source>
          <year>1996</year>
          <volume>37</volume>
          <fpage>1557</fpage>
          <lpage>1562</lpage>
          <pub-id pub-id-type="pmid">8790218</pub-id>
        </element-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lambrecht</surname>
              <given-names>RM</given-names>
            </name>
            <name>
              <surname>Woodhouse</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Phillips</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Wolczak</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Qureshi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Reyes</surname>
              <given-names>ED</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Investigational study of iodine-124 with a positron camera</article-title>
          <source>Am J Physiol Imaging</source>
          <year>1988</year>
          <volume>3</volume>
          <fpage>197</fpage>
          <lpage>200</lpage>
          <pub-id pub-id-type="pmid">3265064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Eschmann</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Reischl</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Bilger</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Kupferschlager</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Thelen</surname>
              <given-names>MH</given-names>
            </name>
            <name>
              <surname>Dohmen</surname>
              <given-names>BM</given-names>
            </name>
            <name>
              <surname>Eur</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET</article-title>
          <source>Nucl Med Mol Imaging</source>
          <year>2002</year>
          <volume>29</volume>
          <fpage>760</fpage>
          <pub-id pub-id-type="doi">10.1007/s00259-002-0775-8</pub-id>
        </element-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Crawford</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Flower</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Pratt</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Hill</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Zweit</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>McCready</surname>
              <given-names>VR</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thyroid volume measurement in thyrotoxic patients: comparison between ultrasonography and iodine-124 positron emission tomography</article-title>
          <source>Eur J Nucl Med</source>
          <year>1997</year>
          <volume>24</volume>
          <fpage>1470</fpage>
          <lpage>1478</lpage>
          <pub-id pub-id-type="doi">10.1007/s002590050176</pub-id>
          <pub-id pub-id-type="pmid">9391181</pub-id>
        </element-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flower</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>al-Saadi</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Harmer</surname>
              <given-names>CL</given-names>
            </name>
            <name>
              <surname>McCready</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Ott</surname>
              <given-names>RJ</given-names>
            </name>
          </person-group>
          <article-title>Dose-response study on thyrotoxic patients undergoing positron emission tomography and radioiodine therapy</article-title>
          <source>Eur J Nucl Med</source>
          <year>1994</year>
          <volume>21</volume>
          <fpage>531</fpage>
          <lpage>536</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00173041</pub-id>
          <pub-id pub-id-type="pmid">8082669</pub-id>
        </element-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Flower</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Irvine</surname>
              <given-names>AT</given-names>
            </name>
            <name>
              <surname>Ott</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Kabir</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>McCready</surname>
              <given-names>VR</given-names>
            </name>
            <name>
              <surname>Harmer</surname>
              <given-names>CL</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Thyroid imaging using positron emission tomography-a comparison with ultrasound imaging and conventional scintigraphy in thyrotoxicosis</article-title>
          <source>Br J Radiol</source>
          <year>1990</year>
          <volume>63</volume>
          <fpage>325</fpage>
          <lpage>330</lpage>
          <pub-id pub-id-type="doi">10.1259/0007-1285-63-749-325</pub-id>
          <pub-id pub-id-type="pmid">2198979</pub-id>
        </element-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Ott</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Batty</surname>
              <given-names>V</given-names>
            </name>
            <name>
              <surname>Webb</surname>
              <given-names>BS</given-names>
            </name>
            <name>
              <surname>Flower</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Leach</surname>
              <given-names>MO</given-names>
            </name>
            <name>
              <surname>Clack</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Measurement of radiation dose to the thyroid using positron emission tomography</article-title>
          <source>Br J Radiol</source>
          <year>1987</year>
          <volume>60</volume>
          <fpage>245</fpage>
          <lpage>251</lpage>
          <pub-id pub-id-type="doi">10.1259/0007-1285-60-711-245</pub-id>
          <pub-id pub-id-type="pmid">3494482</pub-id>
        </element-citation>
      </ref>
      <ref id="CR15">
        <label>15.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frey</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Flatted</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>De Gautard</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Widgren</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Jeavons</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Tomographic imaging of the human thyroid using 124I</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>1986</year>
          <volume>63</volume>
          <fpage>918</fpage>
          <lpage>927</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem-63-4-918</pub-id>
          <pub-id pub-id-type="pmid">3488999</pub-id>
        </element-citation>
      </ref>
      <ref id="CR16">
        <label>16.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Frey</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Townsend</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Jeavons</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Donath</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>In vivo imaging of the human thyroid with a positron camera using 124I</article-title>
          <source>Eur J Nucl Med</source>
          <year>1985</year>
          <volume>10</volume>
          <fpage>472</fpage>
          <lpage>476</lpage>
          <pub-id pub-id-type="pmid">3874064</pub-id>
        </element-citation>
      </ref>
      <ref id="CR17">
        <label>17.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freudenberg</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Antoch</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Jentzen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Pink</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Knust</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Gorges</surname>
              <given-names>R</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Value of 124I-PET/CT in staging of patients with differentiated thyroid cancer</article-title>
          <source>Eur Radiol</source>
          <year>2004</year>
          <volume>14</volume>
          <fpage>2092</fpage>
          <lpage>2098</lpage>
          <pub-id pub-id-type="doi">10.1007/s00330-004-2350-0</pub-id>
          <pub-id pub-id-type="pmid">15232708</pub-id>
        </element-citation>
      </ref>
      <ref id="CR18">
        <label>18.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freudenberg</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Antoch</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Gorges</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Knust</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Pink</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Jentzen</surname>
              <given-names>W</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Combined PET/CT with iodine-124 in diagnosis of spread metastatic thyroid carcinoma: a case report</article-title>
          <source>Eur Radiol</source>
          <year>2003</year>
          <volume>13</volume>
          <issue>Suppl</issue>
          <fpage>L19</fpage>
          <lpage>L23</lpage>
          <pub-id pub-id-type="doi">10.1007/s00330-003-1884-x</pub-id>
          <pub-id pub-id-type="pmid">15018161</pub-id>
        </element-citation>
      </ref>
      <ref id="CR19">
        <label>19.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Georges</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Antoch</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Brandau</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Freudenberg</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Knust</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Dutschka</surname>
              <given-names>K</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Kombinierte PET/CT mit dem Positronenstrahler 124I bei metastasierten follikularen Schilddrusenkarzinom</article-title>
          <source>Nuklearmedizin</source>
          <year>2002</year>
          <volume>5</volume>
          <fpage>N69</fpage>
          <lpage>N71</lpage>
        </element-citation>
      </ref>
      <ref id="CR20">
        <label>20.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lubberink</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>van Schie</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>de Jong</surname>
              <given-names>HW</given-names>
            </name>
            <name>
              <surname>van Dongen</surname>
              <given-names>GA</given-names>
            </name>
            <name>
              <surname>Teule</surname>
              <given-names>GJ</given-names>
            </name>
          </person-group>
          <article-title>Acquisition settings for PET of 124I administered simultaneously with therapeutic amounts of 131I</article-title>
          <source>J Nucl Med</source>
          <year>2006</year>
          <volume>47</volume>
          <fpage>1375</fpage>
          <lpage>1381</lpage>
          <pub-id pub-id-type="pmid">16883019</pub-id>
        </element-citation>
      </ref>
      <ref id="CR21">
        <label>21.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Van Tol</surname>
              <given-names>KM</given-names>
            </name>
            <name>
              <surname>Jager</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>de Vries</surname>
              <given-names>EG</given-names>
            </name>
            <name>
              <surname>Piers</surname>
              <given-names>DA</given-names>
            </name>
            <name>
              <surname>Boezen</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Sluiter</surname>
              <given-names>WJ</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Outcome in patients with differentiated thyroid cancer with negative diagnostic whole-body scanning and detectable stimulated thyroglobulin</article-title>
          <source>Eur J Endocrinol</source>
          <year>2003</year>
          <volume>148</volume>
          <fpage>589</fpage>
          <lpage>596</lpage>
          <pub-id pub-id-type="doi">10.1530/eje.0.1480589</pub-id>
          <pub-id pub-id-type="pmid">12773129</pub-id>
        </element-citation>
      </ref>
      <ref id="CR22">
        <label>22.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Glaser</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Luthra</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Brady</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Applications of positron-emitting halogens in PET oncology (review)</article-title>
          <source>Int J Oncol</source>
          <year>2003</year>
          <volume>22</volume>
          <fpage>253</fpage>
          <lpage>267</lpage>
          <pub-id pub-id-type="pmid">12527920</pub-id>
        </element-citation>
      </ref>
      <ref id="CR23">
        <label>23.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Johansson</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Mattsson</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Nosslin</surname>
              <given-names>B</given-names>
            </name>
            <name>
              <surname>Leide-Svegborn</surname>
            </name>
          </person-group>
          <article-title>Effective dose from radiopharmaceuticals</article-title>
          <source>Eur J Nucl Med</source>
          <year>1992</year>
          <volume>19</volume>
          <fpage>933</fpage>
          <lpage>938</lpage>
          <pub-id pub-id-type="doi">10.1007/BF00175858</pub-id>
          <pub-id pub-id-type="pmid">1308762</pub-id>
        </element-citation>
      </ref>
      <ref id="CR24">
        <label>24.</label>
        <mixed-citation publication-type="other">Berman M, Braverman LE, Burke J, et al. Report No.5 I-123, I-124, I-125, I-126, I-130, I-131, I-132 as sodium iodide. In: Loevinger R, Budinger TF, Watson EE, editors. MIRD primer for absorbed dose calculations. New York: The Society of Nuclear Medicine; 1991. p. 49-54.</mixed-citation>
      </ref>
      <ref id="CR25">
        <label>25.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Sgouros</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Kolbert</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Sheikh</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Pentlow</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Mun</surname>
              <given-names>EF</given-names>
            </name>
            <name>
              <surname>Barth</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Patient-specific dosimetry for <sup>131</sup>I thyroid cancer therapy using <sup>124</sup>I PET and 3-dimensional-internal dosimetry (3D-ID) software</article-title>
          <source>J Nucl Med</source>
          <year>2004</year>
          <volume>8</volume>
          <fpage>1366</fpage>
          <lpage>1372</lpage>
        </element-citation>
      </ref>
      <ref id="CR26">
        <label>26.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Erdi</surname>
              <given-names>YE</given-names>
            </name>
            <name>
              <surname>Macapinlac</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Larson</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Erdi</surname>
              <given-names>AK</given-names>
            </name>
            <name>
              <surname>Yeung</surname>
              <given-names>H</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Radiation dose assessment for I-131 therapy of thyroid cancer using I-124 PET imaging</article-title>
          <source>Clin Positron Imaging</source>
          <year>1999</year>
          <volume>2</volume>
          <fpage>41</fpage>
          <lpage>46</lpage>
          <pub-id pub-id-type="doi">10.1016/S1095-0397(99)00004-7</pub-id>
          <pub-id pub-id-type="pmid">14516552</pub-id>
        </element-citation>
      </ref>
      <ref id="CR27">
        <label>27.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Joensuu</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Ahonen</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose</article-title>
          <source>J Nucl Med</source>
          <year>1987</year>
          <volume>28</volume>
          <fpage>910</fpage>
          <lpage>914</lpage>
          <pub-id pub-id-type="pmid">3572549</pub-id>
        </element-citation>
      </ref>
      <ref id="CR28">
        <label>28.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Freudenberg</surname>
              <given-names>LS</given-names>
            </name>
            <name>
              <surname>Jentzen</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>G&#xF6;rges</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Petrich</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Marlowe</surname>
              <given-names>RJ</given-names>
            </name>
            <name>
              <surname>Knust</surname>
              <given-names>J</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title><sup>124</sup>I-PET dosimetry in advanced differentiated thyroid cancer: therapeutic impact</article-title>
          <source>Nuklearmedizin</source>
          <year>2007</year>
          <volume>46</volume>
          <fpage>121</fpage>
          <lpage>128</lpage>
          <pub-id pub-id-type="pmid">17690789</pub-id>
        </element-citation>
      </ref>
      <ref id="CR29">
        <label>29.</label>
        <mixed-citation publication-type="other">Jentzen W, Weise R, Kupferschl&#xE4;ger J, Freudenberg L, Brandau W, Bares R, et al. Iodine-124 PET dosimetry in differentiated thyroid cancer: recovery coefficient in 2D and 3D modes for PET(/CT) systems. Eur J Nucl Med Mol Imaging 2007 (in press); DOI 10.1007/s00259-007-0554-7.</mixed-citation>
      </ref>
      <ref id="CR30">
        <label>30.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Pacini</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Lippi</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Formica</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Elisei</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Anelli</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Ceccarelli</surname>
              <given-names>C</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Therapeutic doses of iodine-131 reveal undiagnosed metastases in thyroid cancer patients with detectable serum thyroglobulin levels</article-title>
          <source>J Nucl Med</source>
          <year>1987</year>
          <volume>28</volume>
          <fpage>1888</fpage>
          <lpage>1891</lpage>
          <pub-id pub-id-type="pmid">3681445</pub-id>
        </element-citation>
      </ref>
      <ref id="CR31">
        <label>31.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Cholewinski</surname>
              <given-names>SP</given-names>
            </name>
            <name>
              <surname>Yoo</surname>
              <given-names>KS</given-names>
            </name>
            <name>
              <surname>Klieger</surname>
              <given-names>PS</given-names>
            </name>
            <name>
              <surname>O&#x2019;Mara</surname>
              <given-names>RE</given-names>
            </name>
          </person-group>
          <article-title>Absence of thyroid stunning after diagnostic whole-body scanning with 185&#xA0;MBq <sup>131</sup>I</article-title>
          <source>J Nucl Med</source>
          <year>2000</year>
          <volume>41</volume>
          <fpage>1198</fpage>
          <lpage>1202</lpage>
          <pub-id pub-id-type="pmid">10914909</pub-id>
        </element-citation>
      </ref>
      <ref id="CR32">
        <label>32.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Park</surname>
              <given-names>HM</given-names>
            </name>
            <name>
              <surname>Perkins</surname>
              <given-names>OW</given-names>
            </name>
            <name>
              <surname>Edmondson</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Schnute</surname>
              <given-names>RB</given-names>
            </name>
            <name>
              <surname>Manatunga</surname>
              <given-names>A</given-names>
            </name>
          </person-group>
          <article-title>Influence of diagnostic radioiodines on the uptake of ablative dose of iodine-131</article-title>
          <source>Thyroid</source>
          <year>1994</year>
          <volume>4</volume>
          <fpage>49</fpage>
          <lpage>54</lpage>
          <pub-id pub-id-type="doi">10.1089/thy.1994.4.49</pub-id>
          <pub-id pub-id-type="pmid">8054861</pub-id>
        </element-citation>
      </ref>
      <ref id="CR33">
        <label>33.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jeevanram</surname>
              <given-names>RK</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>DH</given-names>
            </name>
            <name>
              <surname>Sharma</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Ganatra</surname>
              <given-names>RD</given-names>
            </name>
          </person-group>
          <article-title>Influence of initial large dose on subsequent uptake of therapeutic radioiodine in thyroid cancer patients</article-title>
          <source>Int J Rad Appl Instrum B</source>
          <year>1986</year>
          <volume>13</volume>
          <fpage>277</fpage>
          <lpage>279</lpage>
          <pub-id pub-id-type="doi">10.1016/0883-2897(86)90108-X</pub-id>
          <pub-id pub-id-type="pmid">3771260</pub-id>
        </element-citation>
      </ref>
      <ref id="CR34">
        <label>34.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Muratet</surname>
              <given-names>JP</given-names>
            </name>
            <name>
              <surname>Daver</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Minier</surname>
              <given-names>JF</given-names>
            </name>
            <name>
              <surname>Larra</surname>
              <given-names>F</given-names>
            </name>
          </person-group>
          <article-title>Influence of scanning doses of iodine-131 on subsequent first ablative treatment outcome in patients operated on for differentiated thyroid carcinoma</article-title>
          <source>J Nucl Med</source>
          <year>1998</year>
          <volume>39</volume>
          <fpage>1546</fpage>
          <lpage>1550</lpage>
          <pub-id pub-id-type="pmid">9744340</pub-id>
        </element-citation>
      </ref>
      <ref id="CR35">
        <label>35.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Leger</surname>
              <given-names>FA</given-names>
            </name>
            <name>
              <surname>Izembart</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Dagousset</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Barritault</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Baillet</surname>
              <given-names>G</given-names>
            </name>
            <name>
              <surname>Chevalier</surname>
              <given-names>A</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>Decreased uptake of therapeutic doses of iodine-131 after 185-MBq iodine-131 diagnostic imaging for thyroid remnants in differentiated thyroid carcinoma</article-title>
          <source>Eur J Nucl Med</source>
          <year>1998</year>
          <volume>25</volume>
          <fpage>242</fpage>
          <lpage>246</lpage>
          <pub-id pub-id-type="doi">10.1007/s002590050223</pub-id>
          <pub-id pub-id-type="pmid">9580856</pub-id>
        </element-citation>
      </ref>
      <ref id="CR36">
        <label>36.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Morris</surname>
              <given-names>LF</given-names>
            </name>
            <name>
              <surname>Waxman</surname>
              <given-names>AD</given-names>
            </name>
            <name>
              <surname>Braunstein</surname>
              <given-names>GD</given-names>
            </name>
          </person-group>
          <article-title>The nonimpact of thyroid stunning: remnant ablation rates in <sup>131</sup>I-scanned and nonscanned individuals</article-title>
          <source>J Clin Endocrinol Metab</source>
          <year>2001</year>
          <volume>86</volume>
          <fpage>3507</fpage>
          <lpage>3511</lpage>
          <pub-id pub-id-type="doi">10.1210/jcem.86.8.7717</pub-id>
          <pub-id pub-id-type="pmid">11502771</pub-id>
        </element-citation>
      </ref>
      <ref id="CR37">
        <label>37.</label>
        <element-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Waxman</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Ramanna</surname>
              <given-names>L</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Chapman</surname>
              <given-names>D</given-names>
            </name>
            <name>
              <surname>Brachman</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Tanasescu</surname>
              <given-names>D</given-names>
            </name>
            <etal/>
          </person-group>
          <article-title>The significance of I-131 scan dose in patients with thyroid cancer: determination of ablation: concise communication</article-title>
          <source>J Nucl Med</source>
          <year>1981</year>
          <volume>22</volume>
          <fpage>861</fpage>
          <lpage>865</lpage>
          <pub-id pub-id-type="pmid">7288483</pub-id>
        </element-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>